Figure 1.

H3122 but not H2228 cells are sensitive to vincristine and ALK-TKIs. (A–C). Lung cancer cells were treated with increasing doses of vincristine (A), crizotinib (B) and ceritinib (C) for 72 h. Cell viability was determined using CellTiter-Glo assays. The IC₅₀ values were calculated using the Prism 9.0 software. Data represent the mean of three biological replicates in each column; the bars denote ±SD. (D). Table summarises the IC₅₀ of vincristine and ALK inhibitors in lung cancer cell lines harbouring major oncogenic mutations.